Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy

Página do item simplificado
dc.citation.volume12]
dc.contributor.authorBoudreault, Katherine
dc.contributor.authorJustus, Sally
dc.contributor.authorSengillo, Jesse D.
dc.contributor.authorSchuerch, Kaspar
dc.contributor.authorLee, Winston
dc.contributor.authorCabral, Thiago [UNIFESP]
dc.contributor.authorTsang, Stephen H.
dc.coverageLondon
dc.date.accessioned2020-06-26T16:30:15Z
dc.date.available2020-06-26T16:30:15Z
dc.date.issued2017
dc.description.abstractBackground: Autoimmune retinopathy (AIR) is a rare but potentially blinding condition that is often underdiagnosed. Common features in AIR presentation include rapidly progressive vision loss with abnormal electrophysiological responses of the retina associated with positive anti-retinal antibodies. AIR is also challenging to treat, and thus, the introduction of new potential therapeutic agents is welcomed. The goal of this communication is to assess the effects of rituximab infusions on electroretinogram (ERG) responses and visual function outcomes in patients with non-paraneoplastic autoimmune retinopathy (npAIR). Results: Following infusion(s), three out of five patients showed no evidence of disease progression or improved, while two patients continued to progress on ERG. One patient demonstrated improvement in visual acuity (2 lines) in both eyes. ERG responses provided objective monitoring of patients' visual function and response to immunosuppression over time. Conclusions: These findings suggest that patients with npAIR unresponsive to other immunosuppression therapies may benefit from rituximab infusion, although stabilization rather than improvement was more frequently the outcome in our case series. Furthermore, regularly scheduled ERG follow-up examinations are recommended for monitoring patients' progression during treatment.en
dc.description.affiliationColumbia Univ, Med Ctr, Jonas Childrens Vis Care, New York, NY 10027 USA
dc.description.affiliationColumbia Univ, Med Ctr, Bernard & Shirlee Brown Glaucoma Lab, New York, NY 10027 USA
dc.description.affiliationColumbia Univ, Dept Ophthalmol, New York, NY 10027 USA
dc.description.affiliationSuny Downstate Med Ctr, Brooklyn, NY 11203 USA
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil
dc.description.affiliationFed Univ Espirito Santo UFES, Dept Ophthalmol, Vitoria, Brazil
dc.description.affiliationColumbia Univ, Coll Phys & Surg, Inst Human Nutr, Dept Pathol & Cell Biol, New York, NY USA
dc.description.affiliationUnifespUniv Fed Sao Paulo UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipNational Institutes of Health
dc.description.sponsorshipNational Cancer Institute Core
dc.description.sponsorshipResearch to Prevent Blindness (RPB)
dc.description.sponsorshipRPB, New York, NY, USA
dc.description.sponsorshipRPB
dc.description.sponsorshipInternational Council of Ophthalmology - Retina Research Foundation
dc.description.sponsorshipTistou and Charlotte Kerstan Foundation
dc.description.sponsorshipSchneeweiss Stem Cell Fund, New York State
dc.description.sponsorshipFoundation Fighting Blindness New York Regional Research Center
dc.description.sponsorshipCrowley Family Fund
dc.description.sponsorshipGebroe Family Foundation
dc.description.sponsorshipIDNational Institutes of Health: 5P30EY019007
dc.description.sponsorshipIDNational Institutes of Health: R01EY018213
dc.description.sponsorshipIDNational Institutes of Health: R01EY024698
dc.description.sponsorshipIDNational Institutes of Health: R01EY026682
dc.description.sponsorshipIDNational Institutes of Health: R21AG050437]
dc.description.sponsorshipIDNational Cancer Institute Core: 5P30CA013696
dc.description.sponsorshipIDRPB
dc.description.sponsorshipIDInternational Council of Ophthalmology - Retina Research Foundation
dc.description.sponsorshipIDTistou and Charlotte Kerstan Foundation
dc.description.sponsorshipIDSchneeweiss Stem Cell Fund: C029572
dc.description.sponsorshipIDFoundation Fighting Blindness New York Regional Research Center: C-NY05-0705-0312
dc.description.sponsorshipIDCrowley Family Fund
dc.description.sponsorshipIDGebroe Family Foundation
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1186/s13023-017-0680-7]
dc.identifier.citationOrphanet Journal Of Rare Diseases. London, v. 12, p. -, 2017.
dc.identifier.doi10.1186/s13023-017-0680-7
dc.identifier.fileWOS000405839900001.pdf
dc.identifier.issn1750-1172
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/53445
dc.identifier.wosWOS:000405839900001
dc.language.isoeng
dc.publisherBiomed Central Ltd
dc.relation.ispartofOrphanet Journal Of Rare Diseases
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAutoimmune retinopathyen
dc.subjectRituximaben
dc.subjectTreatmenten
dc.subjectMulti-modal imagingen
dc.subjectElectroretinographyen
dc.titleEfficacy of rituximab in non-paraneoplastic autoimmune retinopathyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000405839900001.pdf
Tamanho:
12.93 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos